Corbus Pharmaceuticals Holdings, Inc. · MUN:3371

Corbus Pharmaceuticals Holdings, Inc. financial statements

Corbus Pharmaceuticals Holdings, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000881.7K3.94M36.1M4.82M2.44M1.91M
Cost of revenue233.0K600.0K31.2M1.49M1.64M98.3K89.6M48.6M26.0M15.4M
Gross profit-233.0K-600.0K-31.2M-1.49M-757.5K3.94M-53.5M-43.8M-23.6M-13.5M
Research and development70.1M32.2M31.2M16.1M36.4M98.3M89.6M48.6M26.0M15.4M
Selling, general and administrative15.2M16.5M13.9M18.7M20.4M28.5M23.6M13.0M8.96M6.46M
Operating income-85.3M-48.7M-45.1M-39.8M-56.0M-122.8M-77.1M-56.7M-32.6M-20.0M
Depreciation and amortization233.0K588.0K641.0K763.0K999.8K1.12M739.4K493.9K255.7K87.7K
EBITDA-85.1M-48.1M-44.4M-39.1M-55.0M-121.7M-76.4M-56.3M-32.3M-19.9M
Interest expense01.87M3.86M3.10M2.71M1.13M003.63K3.12K
Income before tax-78.5M-40.2M-44.6M-42.3M-45.6M-111.3M-71.5M-55.7M-32.4M-20.0M
Income tax0013.5M-87.8K35.0K-2.30M1.08M-396.9K13.6K
Net income-78.5M-40.2M-44.6M-42.3M-45.6M-111.3M-71.5M-55.7M-32.4M-20.0M
Earnings per share, basic-5.90-3.68-10.31-10.15-11.15-1.42-1.12-0.98-0.65-0.49
Earnings per share, diluted-5.90-3.68-10.31-10.15-11.15-1.42-1.12-0.98-0.65-0.49

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents28.5M17.2M13.7M17.0M25.0M85.4M31.7M41.7M62.5M15.0M
Short-term investments134.8M131.9M7.18M42.2M72.6M0159.0K150.0K
Receivables1.50M2.58M2.68M1.33M
Inventory350.0K-2.68M00
Current assets167.0M153.0M23.5M60.2M100.2M92.1M38.2M44.2M65.5M17.4M
Property, plant and equipment159.0K385.0K973.0K1.61M2.39M4.07M5.08M2.71M1.43M435.3K
Goodwill00
Total assets168.2M155.9M28.3M66.3M107.7M102.3M49.1M47.0M67.0M17.9M
Accounts payable2.21M4.79M3.18M2.17M1.78M7.38M11.1M6.35M3.13M3.42M
Current liabilities20.7M11.8M31.9M12.6M17.0M31.9M34.9M18.1M8.20M8.90M
Long-term debt016.0M15.6M18.0M05.00K
Total debt1.63M3.24M17.9M21.6M21.2M21.2M9.45M394.3K332.9K276.4K
Total liabilities20.7M13.5M35.2M33.3M38.6M57.0M43.0M19.5M9.19M8.97M
Shareholders' equity147.5M142.4M-6.91M33.0M69.1M45.3M6.16M27.5M57.8M8.92M
Shares outstanding17.6M12.2M4.42M4.17M4.17M98.9M64.7M57.2M55.6M44.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-64.5M-41.8M-36.1M-37.5M-48.2M-99.7M-45.7M-30.1M-27.8M-13.6M
Capital spending-7.00K00-13.4K-54.2K-484.5K-2.74M-2.30M-707.4K-353.0K
Free cash flow-64.5M-41.8M-36.1M-37.6M-48.2M-100.2M-48.5M-32.4M-28.5M-13.9M
Cash from investing-1.64M-121.3M35.6M30.1M-73.4M-484.5K-2.74M-2.30M-707.4K-353.0K
Cash from financing77.4M166.6M-2.82M-533.6K60.8M154.9M38.5M11.4M76.0M16.7M
Dividends paid00
Share buybacks142.2M40.7M12.1M78.9M16.7M
Change in cash11.3M3.47M-3.28M-8.00M-60.8M54.7M-10.00M-20.9M47.5M2.82M